Orzeyful (oveporexton): FDA approval, pivotal trial and safety
Approved
Type
New molecular entity · Oral
FDA-approved use
To treat narcolepsy type 1Wording from FDA's list of novel approvals.
FDA review
Priority reviewOrphan drug
Company
Takeda
Application
NDA 220860
Specialty
Neurology
At a glance
Orzeyful is the first orexin receptor agonist, and the first drug aimed at the missing orexin signal that causes narcolepsy type 1 rather than at its downstream symptoms. In two 12-week phase 3 trials it lengthened the time patients could stay awake on the Maintenance of Wakefulness Test (MWT) by 14 to 20 minutes (on a 40-minute test where 20 or more is normal) and cut weekly cataplexy by about four fifths. Increased urinary frequency and short-lived insomnia affected most patients.
What it is and how it works
Narcolepsy type 1 results from the loss of the hypothalamic neurons that make orexin (hypocretin), the peptide that keeps people awake and stabilizes muscle tone during wakefulness. Oveporexton is an oral small molecule that selectively activates the orexin type 2 receptor, standing in for the lost peptide. Current treatments work elsewhere: stimulants and wake-promoting agents increase monoamines, pitolisant acts on histamine H3 receptors, and oxybates consolidate night-time sleep.
Two phase 3, randomized, double-blind, placebo-controlled trials over 12 weeks. First Light compared two doses with placebo (3:3:2); Radiant Light compared one dose with placebo (2:1). Radiant Light is NCT06505031.
Patients
273 people aged 16 to 70 years with narcolepsy type 1 (168 in First Light, 105 in Radiant Light).
Compared with
Placebo
Primary endpoint
Change from baseline to week 12 in mean sleep latency on the MWT (0 to 40 minutes; 20 or more is normal).
Result
Mean sleep latency rose by 14.3 to 19.8 minutes with oveporexton across arms, compared with a change of -0.4 to -0.8 minutes with placebo (adjusted P<0.001 for every comparison).
Other results
Epworth Sleepiness Scale scores fell by 9.7 to 11.8 points with oveporexton versus 1.5 to 1.7 with placebo (normal is 10 or less). Median weekly cataplexy fell by 79.0% to 88.8% versus 27.7% to 39.1% with placebo (adjusted P<0.001 for all).
Safety in the trial
Adverse events in 86% to 89% versus 43% to 54%; increased urinary frequency and transient insomnia in most treated patients.
How does Orzeyful (oveporexton) compare with the alternatives (Sodium oxybate and low-sodium oxybate, Pitolisant, Solriamfetol) for narcolepsy type 1? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseOpens in a new tab. Nothing is sent until you press Ask. Free to try, more with 2MM+.
Deep research is a core feature of 2MM Max.
Safety signals
In the phase 3 trials, adverse events occurred in 86% to 89% of patients on oveporexton and in 43% to 54% on placebo. Increased urinary frequency and transient insomnia were the most common and occurred in a majority of treated patients. Both trials lasted 12 weeks.
What it competes with
Most patients with narcolepsy type 1 take two or more drugs today, combining a wake-promoting agent for daytime sleepiness with an oxybate or another agent for cataplexy. Oveporexton improved both sleepiness and cataplexy in the same trials; how it combines with, or replaces, existing drugs is not yet tested head to head.
Sodium oxybate and low-sodium oxybateTreat cataplexy and daytime sleepiness by consolidating night sleep; taken at night.
PitolisantHistamine H3 receptor antagonist/inverse agonist for sleepiness and cataplexy.
SolriamfetolDopamine and norepinephrine reuptake inhibitor for excessive daytime sleepiness.
Modafinil or armodafinilWake-promoting agents for daytime sleepiness; no effect on cataplexy.
Amphetamines and methylphenidateStimulants for refractory sleepiness.
Bottom line for clinicians
For narcolepsy type 1, oveporexton is a mechanistically new option with large effects on objective wakefulness, subjective sleepiness and cataplexy at 12 weeks. Warn patients about urinary frequency and early insomnia, and check the label for monitoring. It is approved for type 1, the orexin-deficient form, not for narcolepsy type 2 or other hypersomnias.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated October 27, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.
Get the app